Clinical Trial Update: A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase Ib study of YY-20394 in participants with B-cell hematologic malignancies has completed, evaluating safety and preliminary activity across multiple subtyp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Lymphoplasmacytic Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• YY-20394

Snippet

Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd. | Conditions: Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma | Phase 1 | Status: COMPLETED